Sandoz plans to enter the Eylea biosimilar race

Sandoz is planning to file for regulatory approval in the US and EU for its Eylea (aflibercept) biosimilar in the next few months.

In Q2 2023, Sandoz generated $2.4bn from biosimilar sales. To that end, the company has plans to launch four high-profile biosimilars, including Eylea, and increase their access over the coming years as part of its Act4Biosimilars initiative, especially as it is expected to split completely from its parent company Novartis by the end of 2023.